Quarterly report pursuant to Section 13 or 15(d)

Segment information

v2.3.0.15
Segment information
 3 Months Ended
Sep. 30, 2011
Segment information

I. Segment information:

The Company has two reportable segments based on the nature of products: biotechnology and hematology. Following is financial information relating to the Company’s reportable segments (in thousands):

 

     Quarter Ended
September 30,		  
     2011     2010  

External sales

     

Biotechnology

    $ 72,303      $ 63,041   

Hematology

      5,293        4,904   
  

 

 

    

 

 

  

Consolidated net sales

    $ 77,596      $ 67,945   
  

 

 

    

 

 

  

Earnings before income taxes

     

Biotechnology

    $ 39,984      $ 38,460   

Hematology

      1,918        1,922   
  

 

 

    

 

 

  

Segment earnings before income taxes

      41,902        40,382   

Unallocated corporate expenses and equity method investee losses

      (1,402 )      (1,429 ) 
  

 

 

    

 

 

  

Consolidated earnings before income taxes

    $ 40,500      $ 38,953